The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
In this video, Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, shares insights into how therapy should be tailored for young, fit patients with chronic lymphocytic leukemia (CLL), highlighting the importance of considering biomarker profiles and fixed-duration regimens for those without TP53 aberrations. She suggests that combinations of ibrutinib plus venetoclax or venetoclax plus obinutuzumab may be effective, and that the addition of an anti-CD20 monoclonal antibody may improve responses in specific patient subgroups. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
